236 related articles for article (PubMed ID: 35398462)
21. Natural history of chronic hepatitis B REVEALed.
Chen CJ; Yang HI
J Gastroenterol Hepatol; 2011 Apr; 26(4):628-38. PubMed ID: 21323729
[TBL] [Abstract][Full Text] [Related]
22. Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B.
Papatheodoridis GV; Sypsa V; Dalekos GN; Yurdaydin C; Van Boemmel F; Buti M; Calleja JL; Chi H; Goulis J; Manolakopoulos S; Loglio A; Voulgaris T; Gatselis N; Keskin O; Veelken R; Lopez-Gomez M; Hansen BE; Savvidou S; Kourikou A; Vlachogiannakos J; Galanis K; Idilman R; Esteban R; Janssen HLA; Berg T; Lampertico P
J Hepatol; 2020 Jun; 72(6):1088-1096. PubMed ID: 31981727
[TBL] [Abstract][Full Text] [Related]
23. Cumulative incidence of hepatocellular carcinoma and hepatitis B surface antigen Seroclearance after Nucleos(t) ide analogue-induced hepatitis B e antigen Seroclearance.
Lee HW; Lee JI; Kim S; Kim S; Chang HY; Lee KS
BMC Gastroenterol; 2020 Apr; 20(1):113. PubMed ID: 32305059
[TBL] [Abstract][Full Text] [Related]
24. Similarly low risk of hepatocellular carcinoma after either spontaneous or nucleos(t)ide analogue-induced hepatitis B surface antigen loss.
Yip TC; Wong VW; Tse YK; Liang LY; Hui VW; Zhang X; Li GL; Lui GC; Chan HL; Wong GL
Aliment Pharmacol Ther; 2021 Jan; 53(2):321-331. PubMed ID: 33222272
[TBL] [Abstract][Full Text] [Related]
25. Persistence of intrahepatic hepatitis B virus DNA integration in patients developing hepatocellular carcinoma after hepatitis B surface antigen seroclearance.
Jang JW; Kim JS; Kim HS; Tak KY; Nam H; Sung PS; Bae SH; Choi JY; Yoon SK; Roberts LR
Clin Mol Hepatol; 2021 Jan; 27(1):207-218. PubMed ID: 33317255
[TBL] [Abstract][Full Text] [Related]
26. Effects of Diabetes and Glycemic Control on Risk of Hepatocellular Carcinoma After Seroclearance of Hepatitis B Surface Antigen.
Cheuk-Fung Yip T; Wai-Sun Wong V; Lik-Yuen Chan H; Tse YK; Pik-Shan Kong A; Long-Yan Lam K; Chung-Yan Lui G; Lai-Hung Wong G
Clin Gastroenterol Hepatol; 2018 May; 16(5):765-773.e2. PubMed ID: 29246694
[TBL] [Abstract][Full Text] [Related]
27. Impact of fatty liver on long-term outcomes in chronic hepatitis B: a systematic review and matched analysis of individual patient data meta-analysis.
Wong YJ; Nguyen VH; Yang HI; Li J; Le MH; Wu WJ; Han NX; Fong KY; Chen E; Wong C; Rui F; Xu X; Xue Q; Hu XY; Leow WQ; Goh GB; Cheung R; Wong G; Wong VW; Yu MW; Nguyen MH
Clin Mol Hepatol; 2023 Jul; 29(3):705-720. PubMed ID: 37157776
[TBL] [Abstract][Full Text] [Related]
28. Association Between Seroclearance of Hepatitis B Surface Antigen and Long-term Clinical Outcomes of Patients With Chronic Hepatitis B Virus Infection: Systematic Review and Meta-analysis.
Anderson RT; Choi HSJ; Lenz O; Peters MG; Janssen HLA; Mishra P; Donaldson E; Westman G; Buchholz S; Miller V; Hansen BE
Clin Gastroenterol Hepatol; 2021 Mar; 19(3):463-472. PubMed ID: 32473348
[TBL] [Abstract][Full Text] [Related]
29. HBsAg seroclearance in chronic hepatitis B: implications for hepatocellular carcinoma.
Kim JH; Lee YS; Lee HJ; Yoon E; Jung YK; Jong ES; Lee BJ; Seo YS; Yim HJ; Yeon JE; Park JJ; Kim JS; Bak YT; Byun KS
J Clin Gastroenterol; 2011 Jan; 45(1):64-8. PubMed ID: 20535028
[TBL] [Abstract][Full Text] [Related]
30. Spontaneous seroclearance of hepatitis B seromarkers and subsequent risk of hepatocellular carcinoma.
Liu J; Yang HI; Lee MH; Lu SN; Jen CL; Batrla-Utermann R; Wang LY; You SL; Hsiao CK; Chen PJ; Chen CJ;
Gut; 2014 Oct; 63(10):1648-57. PubMed ID: 24225939
[TBL] [Abstract][Full Text] [Related]
31. [Effect of chronic hepatitis B virus DNA negative transformation and HBsAg clearance on the occurrence of hepatocellular carcinoma].
Zhou JL; Wang BQ; Shi YW; You H
Zhonghua Gan Zang Bing Za Zhi; 2019 Nov; 27(11):831-833. PubMed ID: 31941236
[TBL] [Abstract][Full Text] [Related]
32. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability.
Kim GA; Lim YS; An J; Lee D; Shim JH; Kim KM; Lee HC; Chung YH; Lee YS; Suh DJ
Gut; 2014 Aug; 63(8):1325-32. PubMed ID: 24162593
[TBL] [Abstract][Full Text] [Related]
33. Clinical outcomes after spontaneous and nucleos(t)ide analogue-treated HBsAg seroclearance in chronic HBV infection.
Chen YC; Jeng WJ; Chien RN; Chu CM; Liaw YF
Aliment Pharmacol Ther; 2016 Jun; 43(12):1311-8. PubMed ID: 27072504
[TBL] [Abstract][Full Text] [Related]
34. Long-term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis B.
Arase Y; Ikeda K; Suzuki F; Suzuki Y; Saitoh S; Kobayashi M; Akuta N; Someya T; Hosaka T; Sezaki H; Kobayashi M; Kumada H
Am J Med; 2006 Jan; 119(1):71.e9-16. PubMed ID: 16431195
[TBL] [Abstract][Full Text] [Related]
35. Natural history of chronic hepatitis B virus infection in adults with emphasis on the occurrence of cirrhosis and hepatocellular carcinoma.
Chu CM
J Gastroenterol Hepatol; 2000 May; 15 Suppl():E25-30. PubMed ID: 10921378
[TBL] [Abstract][Full Text] [Related]
36. Ethnic differences in incidence of hepatitis B surface antigen seroclearance in a real-life multicenter clinical cohort of 4737 patients with chronic hepatitis B infection.
Nguyen LH; Hoang J; Nguyen NH; Vu VD; Wang C; Trinh HN; Li J; Zhang JQ; Nguyen MH
Aliment Pharmacol Ther; 2016 Aug; 44(4):390-9. PubMed ID: 27363288
[TBL] [Abstract][Full Text] [Related]
37. HBcrAg Predicts Hepatocellular Carcinoma Development in Chronic B Hepatitis Related Liver Cirrhosis Patients Undergoing Long-Term Effective Anti-Viral.
Chang KC; Lin MT; Wang JH; Hung CH; Chen CH; Chiu SY; Hu TH
Viruses; 2022 Nov; 14(12):. PubMed ID: 36560675
[TBL] [Abstract][Full Text] [Related]
38. Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection.
Chen YC; Sheen IS; Chu CM; Liaw YF
Gastroenterology; 2002 Oct; 123(4):1084-9. PubMed ID: 12360470
[TBL] [Abstract][Full Text] [Related]
39. Incorporating Serum Level of Hepatitis B Surface Antigen or Omitting Level of Hepatitis B Virus DNA Does not Affect Calculation of Risk for Hepatocellular Carcinoma in Patients Without Cirrhosis.
Yang HI; Tseng TC; Liu J; Lee MH; Liu CJ; Su TH; Batrla-Utermann R; Chan HL; Kao JH; Chen CJ
Clin Gastroenterol Hepatol; 2016 Mar; 14(3):461-468.e2. PubMed ID: 26598229
[TBL] [Abstract][Full Text] [Related]
40. Enhanced Liver Fibrosis Score Stratifies Hepatocellular Carcinoma Risk in Patients With Hepatitis B Surface Antigen Seroclearance.
Mak LY; Cheung KS; Hui RW; Wong DK; Fung J; Yuen MF; Seto WK
Clin Infect Dis; 2022 Dec; 75(12):2257-2259. PubMed ID: 35594565
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]